SLC5A5 and thyroid cancer: Conversely, lenvatinib administration before 123I treatment decreased the radioiodine uptake of NIS-expressing thyroid cancer in vivo, suggesting that tumor angiogenesis inhibition of lenvatinib affects the radioiodine avidity.